Drugs / ApTOLL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05569720 | Apr → Jun 2022 | stroke disorder | aptaTargets S.L. | Completed | No outcome recorded |
| Phase 1 | NCT05293236 | Jan → Dec 2022 | COVID-19 | Macarena Hernández Jiménez | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04742062 Comparator | Jul 2019 → Feb 2020 | stroke disorder | aptaTargets S.L. | Completed | No outcome recorded |
| Phase 1/2 | NCT04734548 Comparator | Oct 2020 → Jul 2022 | ischemic stroke | aptaTargets S.L. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | aptaTargets S.L. | Results ApTOLL’s secondary analysis data of APRIL 1b/2a trial published in ‘Stroke’ aptatargets.com ↗ |
| 2024-06-06 | aptaTargets S.L. | Results A new study shows the cerebroprotective effects of ApTOLL on mice with acute ischemic stroke aptatargets.com ↗ |
| 2024-05-20 | aptaTargets S.L. | Results Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate myelin in models of multiple sclerosis aptatargets.com ↗
The results demonstrated that ApTOLL reduces inflammatory response and myelin loss and, furthermore, has a remyelinating effect , in other words, it helps to regenerate myelin. |
| 2023-06-20 | aptaTargets S.L. | Results ‘JAMA Neurology’ publishes the results from Phase 1b/2a clinical trial of the neuroprotective drug ApTOLL for acute ischemic stroke aptatargets.com ↗
Patients received randomly ApTOLL or placebo intravenously prior to thrombectomy. |
| 2023-02-28 | aptaTargets S.L. | Regulatory aptaTargets receives PRIME designation from the European Medicines Agency for ApTOLL in ischemic stroke aptatargets.com ↗
aptaTargets has obtained priority medicines (PRIME) designation from the European Medicines Agency (EMA) for the neuroprotectant ApTOLL to improve the treatment of acute ischemic stroke, which accounts for 85% of strokes. |
| 2023-02-08 | aptaTargets S.L. | Results aptaTargets’ ApTOLL reduces mortality from 18% to 5% in a Phase 1b/2a trial in ischemic stroke patients aptatargets.com ↗
The drug ApTOLL, developed by aptaTargets, yielded groundbreaking safety and efficacy results in a Phase 1b/2a clinical trial in patients with acute ischemic stroke in combination with endovascular therapy (EVT). |
| 2022-10-23 | aptaTargets S.L. | Results aptaTargets announces positive preliminary data from the ApTOLL Phase 2a clinical trial for stroke aptatargets.com ↗
aptaTargets today announces that the preliminary results from the Phase 2a APRIL clinical trial for ApTOLL show that it is a safe and well-tolerated neuroprotective drug capable of reducing brain damage and improving the functional outcomes of patients who have suffered acute ischemic stroke. |
| 2022-04-12 | aptaTargets S.L. | Results aptaTargets’ Phase 1b clinical data for ApTOLL published in ‘Molecular Therapy: Nucleic Acids’ journal aptatargets.com ↗
aptaTargets’ Phase 1b clinical trial data for ApTOLL-FIH-01 has been published in the American Society of Gene & Cell Therapy’s Molecular Therapy: Nucleic Acids journal and it shows that the drug ApTOLL has an excellent safety and pharmacokinetic profile. |
| 2021-11-30 | aptaTargets S.L. | Regulatory aptaTargets tests an aptamer in COVID-19 patients aptatargets.com ↗ |
| 2021-06-17 | aptaTargets S.L. | Results aptaTargets makes strides in treatment for stroke patients aptatargets.com ↗
In the first phase of the trial (Ib), 32 patients have been recruited and four dose levels have been administered and, according to preliminary data, ApTOLL has shown an excellent safety profile in patients. |
All press releases naming this drug 21 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ApTOLL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04742062 ↗ |
| Action | Inhibit | “ApTOLL is a Toll-like receptor 4 (TLR4) antagonist” NCT04734548 ↗ |
| Modality | Aptamer | “a promising first-in-class aptamer” PMID 36908619 ↗ Feb 2023 |
| Route | Intravenous | “ApTOLL is administered intravenously” NCT04734548 ↗ |
| Target | TLR4 | “ApTOLL is a Toll-like receptor 4 (TLR4) antagonist” NCT04742062 ↗ |